IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.535,34 +3.416,41 (+6,20%)
Neurocrine Biosciences, Inc. (NBIX)
Después del cierre:
Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1448
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Kevin C. Gorman Ph.D. | CEO & Director | 2,05M | N/A | 1958 |
| Mr. Matthew C. Abernethy | Chief Financial Officer | 1,06M | N/A | 1980 |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 1,22M | N/A | 1964 |
| Mr. Kyle W. Gano Ph.D. | Chief Business Development & Strategy Officer | 990,12k | N/A | 1973 |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1,12M | 4,15M | 1964 |
| Jane Sorensen | Head of Investor Relations | N/A | N/A | N/A |
| Mr. Darin M. Lippoldt Esq. | Chief Legal Officer & Corporate Secretary | 921,01k | 2,98M | 1966 |
| Ms. Julie S. Cooke | Chief Human Resources Officer | N/A | N/A | 1966 |
| Mr. Eric S. Benevich | Chief Commercial Officer | 805k | 295,52k | 1965 |
| Mr. David Warren Boyer | Chief Corporate Affairs Officer | N/A | N/A | 1980 |
Descripción
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Neurocrine Biosciences, Inc., a día 1 de mayo de 2024, es 2. Las puntuaciones base son Auditoría: 3; Tablero: 1; Derechos de los accionistas: 3; Compensación: 5.
